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http://dx.doi.org/10.1016/j.bjps.2017.0
1748-6815/ª 2017 British Association of PSummary Background: Patientswho suffer from scars orwrinkles have several therapeutic op-
tions to improve the appearance of their skin. The available treatment modalities that provide
desirable results are often overtly invasive andentail a risk of undesirable adverse effects. Micro-
needling has recently emerged as a non-ablative alternative for treating patients who are con-
cerned with the aesthetic changes that result from injury, disease or ageing.
Objective: This review aims to evaluate the current evidence in the literature onmicroneedling.
Methods: A systematic literature review was performed by searching the electronic databases
PubMed andGoogle Scholar. The reviewed articles were analysed and compared on study design,
treatment protocol, outcome parameters, efficacy measurement and results to evaluate the
strength of the current evidence.
Results: Microneedling was investigated in experimental settings for its effects on atrophic acne
scars, skin rejuvenation, hypertrophic scars, keloids, striae distensae, androgenetic alopecia, mel-
asmaandacnevulgaris. Severalclinical trialsusedrandomisationandsingle-blindationtostrengthen
the validity of the study outcome. Microneedling showed noteworthy results when used on its own
and when combined with topical products or radiofrequency. When compared with other treat-
ments, it showedsimilar resultsbutwaspreferredduetominimal sideeffectsandshorterdowntime.
Conclusion: This systematic review positions microneedling as a safe and effective therapeutic op-
tion for the treatment of scars andwrinkles. The current literature does show somemethodological
shortcomings,andfurther research is requiredto trulyestablishmicroneedlingasanevidence-based
therapeutic option for treating scars, wrinkles and other skin conditions.
ª 2017 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier
Ltd. All rights reserved..com (L. Ramaut).
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Although topical therapy and invasive surgery have their
specific indications in skin treatment, methods that stim-
ulate the body’s own regenerative mechanisms have
currently gained popularity. Ablative modalities such as
lasers, peelings and dermabrasion are based on partial
removal of the epidermis to trigger the growth of new skin
to replace scarred or aged tissue.1 Experience has shown
that injuring the deeper layers of the skin entails a risk of
prolonged healing times, fibrosis of the papillary dermis,
excessive scarring, increased photosensitivity and irregular
pigmentation.2e4 These problems prompted the develop-
ment of non-ablative methods that owe their efficacy to
triggering dermal neocollagenesis while preserving the
stratum corneum and the epidermal barrier function. The
use of energy (e.g. non-ablative lasers, fractional lasers,
and intense pulsed light) for this purpose still entails some
thermal injury and necrosis,5 while the use of small needles
for percutaneous collagen induction reaches the papillary
and reticular dermis in a purely mechanical way. Each in-
dividual micro lesion is perceived by the skin as injury, but
because the epidermal barrier is minimally disrupted,
scarless wound healing will occur. This wound stage is
characterised by the presence of transforming growth fac-
tor-b3 (TGF-b3), which can be traced immunohistologically
and highlights the activity of non-inflammatory wound
healing.6
Microneedling has by now found its way into clinical
practice. The roller device is a drum-shaped tool with a
cylindrical head that is rolled back and forth to induce
thousands of tiny pores in the papillary dermis (Figures 1and 2). In addition, there is an electronic pen-shaped de-
vice that has adjustable settings to control speed and depth
of needle penetration (Figure 3). The unique, non-invasive
penetration of the skin that is caused by microneedling can
also serve as a way to deliver treatments like topical
products or radiofrequency, without causing unnecessary
damage to nearby structures. Products such as platelet rich
plasma (PRP) and human stem cell conditioned medium
(hESC-EPC) are used to enhance the mechanism of percu-
taneous collagen induction by delivering extra growth fac-
tors, while others are combined with microneedling to
enhance their penetration and effects [e.g. Minoxidil,
depigmenting serum and tranexamic acid (TA)]. The de-
livery of radiofrequency through a fractional microneedling
Figure 2 Dermal micro-injury induced by microneedling.
Figure 3 Electrical pen.
Table 1 Search results.
Google Scholar PubMed
Search term ((((microneedling)
OR percutaneous
collagen induction) OR
skin needling)
OR dermaroller) OR
dermal needling
All in title:
microneedling OR
‘dermal needling’ OR
‘percutaneous collagen
induction’ OR
‘skin needling’ OR
dermaroller
Results 139 156
Microneedling: A systematic review of the literature 3radiofrequency (FMRF) device causes thermal injury for
therapeutic purposes directly to the dermis by generating a
current between paired insulated microneedles. This
overcomes the problem of poor penetration depth of bi-
polar radiofrequency and avoids the thermal damage that
occurs with higher levels of energy, which are necessary for
penetration.7
The trigger to form new skin can have a therapeutic
benefit when injury, disease or ageing cause aesthetic
changes in the skin. The advantage of avoiding the risks of
pigmentation changes or scarring when compared to laser
resurfacing and peelings makes it a valuable therapeutic
alternative. Because microneedling is a simple treatment
with a low complication rate, it was easily applied in
experimental settings, and several applications have yet
been explored. However, no evidence-based guidelines are
presently available. This paper examines the current level
of evidence by reviewing randomised controlled trials,
controlled clinical trials and prospective clinical trials that
assess the effects of microneedling on its own and com-
bined with topical products or radiofrequency. All reports
were critically evaluated for methodological strengths and
weaknesses, and their data were summarised to estimate
the existing evidence and to discuss which lack of evidence
needs to be addressed in future studies.Methods
A systematic review was performed following the PRISMA
guidelines. A search for peer-reviewed published articles
was performed on the electronic databases PubMed and
Google Scholar, followed by a screening of the bibliogra-
phies of the included reports. Search terms included
Microneedling, Percutaneous Collagen Induction, Derma-
roller, Dermal Needling, Dermal Rolling, Micro Needle and
Skin Needling. All terms were obtained from medical
literature that describes microneedling and were combined
with the Boolean operator ‘OR’ into one major search filter
(Table 1). No limitations or language restrictions were set.
The last search was conducted on the 12th of August
2016. The retrieved articles were assessed for eligibility by
screening study characteristics and outcome parameters.
Randomised controlled trials, controlled clinical trials and
clinical trials were included. Treatment protocols were
accepted when they included microneedling alone, micro-
needling with topical products as well as FMRF. Studies that
used microneedling in combination with other treatments
that did not specify the additional benefit of microneedling
in comparison with a control group were not included.
Microneedling had to be a clearly determined variable in
the research. An exception was made for FMRF because of
its explicit technical contribution to the mechanism of
radiofrequency delivery. Studies were allowed to use active
and inactive controls. Outcome measures were screened
for the presence of patient- and observer-based assessment
and the mentioning of adverse effects.
Methodological data were extracted from the reports on
a selection of study characteristics and were summarised in
Table 2. The heterogeneity was reduced by grouping the
reports on indication and design. Outcome data were
extracted on clinical improvement reported by patient and
observer, and numerical and histological outcomes. The
statistically significant differences compared to control
were simplified to a double plus or double minus. The sta-
tistically significant differences compared to baseline
(outcomes in prospective clinical trials) were simplified to a
single plus or minus. Adverse effects were simplified to a
symbol when a statistical analysis was carried out.
Outcome parameters based on the judgement of patients
and observers inevitably carry a subjective component.
There are several well-known methodological constructions
available to prevent bias from affecting the validity of find-
ings. All included RCTs and CCTs were screened for their use
of randomisation, blinding, and full outcome reporting.
Attrition bias was evaluated by screening the exclusion
Table 2 Methods.
Participants Dropouts Intervention Comparison Efficacy measurement No. of
treatments
Follow-
upCat Num Histo
Acne vulgaris
CT
Kim et al. 25 0 FMRF baseline x x 3 12
Lee et al. 20 0 FMRF baseline x x 1 8
Androgenetic alopecia
RCT
Dhurat et al. 100 6 MN þ minoxidil MN x x 12 12
CT
Dhurat et al. 4 0 MN þ minoxidil baseline x 12 72
Atrophic acne scars
RCT
Alam et al. 20 5 MN negative control x 3 24
Chae et al. 40 0 FMRF fractional laser
(1550 nm)
x 3 20
Cachafeiro et al. 46 4 MN fractional laser
(1340 nm)
x 3 24
Lehata et al. 39 1 MN þ TCA fractional laser x 6 48
Lehata et al. 30 3 MN TCA-CROSS x 4 4
Lehata et al. 24 4 MN þ TCA TCA-CROSS x 4 32
Min et al. 23 3 FMRF bipolar RF x x x 2 8
Nofal et al. 45 0 MN þ PRP TCA-CROSS
intradermal PRP
x 3 2
CCT
Asif et al. 50 0 MN þ PRP MN þ distilled
water
x 3 12
Chawla et al. 30 3 MN þ PRP MN þ vC x 4 1
Fabroccini et al. 12 0 MN MN þ PRP x 2 32
Jaishree S et al. 30 0 MN MN þ GA peel x 5 12
Puri et al. 30 0 MN TCA-CROSS x 4 16
CT
Dogra et al. 36 6 MN baseline x 5 4
El-Domyati et al. 10 0 MN baseline x x 6 2
Fabroccini et al. 60 0 MN baseline x x 3 40
Fabroccini et al. 32 0 MN baseline x x 2 8
Imrad Majid 37 1 MN baseline x 4 8
Lotfi et al. 30 0 MN baseline x x 5 8
Kaftan et al. 25 0 MN baseline x 2 4
Burn scars
RCT
Busch et al. 20 1 MN þ NCASCS MN, neg co x x 1 48
CT
Aust et al. 16 0 MN baseline x x 4 48
Hypertrophic scars and keloids
RCT
Fabbrocini et al. 20 0 MN þ Sili Gel MN alone,
SG alone
x x 3 12
Melasma
RCT
Budamakuntla et al. 60 8 MN þ TA injection TA x 3 12
CCT
Fabroccini et al. 20 0 MN þ depigmn
serum
serum x x 2 12
Skin rejuvenation
RCT
Lee et al. 25 0 MN þ hESC-EPC MN x x 5 2
4 L. Ramaut et al.
Table 2 (continued )
Participants Dropouts Intervention Comparison Efficacy measurement No. of
treatments
Follow-
upCat Num Histo
CT
El-Domyati et al. 10 0 MN baseline x x 6 2
Fabroccini et al. 10 0 MN Baseline x x
Fabroccini et al. 8 0 MN Baseline x x 2 32
Gold et al. 49 4 FMRF Baseline x 3 12
Kim et al. 11 0 FMRF Baseline x 3 12
Striae
CCT
Khater et al. 20 0 MN Fractional
laser (CO2)
x x 3 24
CT
Park et al. 16 0 MN baseline x x 3 12
Total 1083 49 39 12 7 139
Mean 29,2702 1,5312 3,86111 17,8055
Microneedling: A systematic review of the literature 5criteria and withdrawal. A performance bias is inevitable
because blinding the patients and practitioners for the pro-
cedure of microneedling is impossible. Reports that
mentioned randomisation without mentioning the used tool
were marked with low(*) selection bias. Reports that used
blinding but based their outcome data only on one assessor
without numerical or histological measurement were
marked with low(*) detection bias. Reports that did not
calculate statistical significance of each treatment modality
and the difference between the compared modalities were
marked with low(*) reporting bias. Reports that lacked
patient-reported clinical outcomes weremarked with low()
reporting bias. Attrition bias wasmarked highwhen dropouts
affected the validity of the comparison, which is never the
case in within-patient controlled trials.
Results
Description of included studies
The search results on PubMed and Google Scholar were
screened for duplicates, which resulted in 174 unique records
that were screened on the basis of title and abstract. Eighty-
six articles were excluded, and the remaining 88 reports were
screened on thebasis of full text. Fifty-oneof these 88articles
were excluded because they did not meet our inclusion
criteria. We excluded reviews, letters to editors, expert
opinions, case reports, animal studies, in vitro studies, studies
in progress and treatment protocols that did not specifically
isolate the effects of microneedling in their comparison to a
control group. An additional 10 records were identified
through reference screening. Five of them were included in
this review based on full text. This selection process resulted
in 37 included articles and is summarised in Figure 4.
Because of the heterogeneity of the included studies, a
meta-analysis could not be executed.
Methods
A total of 37 reports were included in this review, of which
13 randomised controlled clinical trials, 7 controlled clinicaltrials and 17 prospective clinical trials. There was within-
patient control in seven split-face studies and in two split-
scar studies, and four of them were randomised. Of the
remaining 12 controlled trials, 9 were randomised. Ten re-
ports used a single-blinded evaluation setup by blinding the
assessors for the used treatment. Sample sizes varied from 4
to 100 with 1063 participants (393 males, 567 females and
103 unknown) and a mean of 29.3. A total of 49 dropouts
were reported, with a mean of 1.53 over all reports. Micro-
needling was investigated in the literature as a possible
treatment for acne vulgaris, androgenetic alopecia, atrophic
acne scars, hypertrophic scars, keloid, melasma, skin reju-
venation and striae distensae. The therapeutic effects of
microneedling were compared to those of fractional lasers
(1550 Er:glass,8 1340 Erbium,9 1540 nm10 and CO2
11), tri-
chloroacetic acid chemical reconstruction of skin scars (TCA-
CROSS),10,12e15 bipolar radiofrequency,7 intradermal injec-
tion of topical products14,16 and silicone gel.17 Methodolog-
ical data are summarised in Table 2.
Treatment protocol
Treatment protocol variables were needle length (mean:
1.5 mm), number of treatments (mean: 3.86), treatment
interval (mean: 4 weeks) and follow-up time (mean: 17.81
weeks).
Twenty-three trials included only microneedling in their
treatment protocol. Twelve trials compared it to baseline,
one trial compared it to a negative control and 10
compared it to a control group that received a different
treatment. Nine trials combined microneedling with topical
products such as PRP,14,18e20 non-cultured stem cell sus-
pension,21 depigmenting serum,22 Minoxidil,23,24 human
stem cell conditioned medium,25 vitamin C19 and TA.16
Six trials investigated the effects of FMRF. One trial
compared it to fractional laser,8 one to bipolar radio-
frequency7 and the others to baseline.26e29 Microneedling
was combined with TCA-CROSS in two trials, with silicone
gel17 and with glycolic acid peel30 each in one trial.
Efficacy measurement
The clinical changes after a therapeutical intervention can
be assessed by the patient and an observer. All studies
Figure 4 Flowchart.
6 L. Ramaut et al.included a subjective outcome evaluation by the assessor
and objectified them with a categorical quantification
through the use of scales (Table 3). These provide numeric
data that enable statistic weighing of the null hypothesis.
The use of an objective measurement tool decreases the
risk of bias entailed by subjective assessment.
Seven studies used a numerical measurement tool.
Acne vulgaris was evaluated by counting the inflammatory
and non-inflammatory lesions and measuring the casual
sebum level and sebum excretion rate.26,31 Lesion count
and the sebum level were also used for the evaluation of
atrophic acne scars.7 The changes in skin topography of
acne scars and skin ageing were objectified with optical
profilometry, a measuring tool that screens the surface
irregularities of a silicon imprint from the treated site by
Fabbrocini et al.32e35 Lee measured skin topography with a
Visiometer.25 Fabbrocini also used ultrasound to measure
epidermal thickness in skin rejuvenation and keloid
scars17,32 and luminance values to evaluate melasma.22
The melanin index was an outcome parameter for depig-
mented hypertrophic scars and skin rejuvenation and was
measured using the Mexameter.21,25
Seven studies evaluated the effects of the treatment
protocol by measuring histological changes.7,11,36e40
Epidermal thickness, collagen fibres, elastin, tropoelastin
and fibroblasts were visualised with several histological
stains. Cytokines and growth factors were visualised with
immunohistologic colouring and polymerase chain reaction
(Table 4).Outcome parameters
All 37 studies included observer-reported clinical out-
comes. Twenty-eight studies included patient-reported
clinical outcomes and 29 studies reported adverse effects.
Effects of interventions
The principal summary measures were defined as differ-
ence in means. Outcomes are summarised in Table 5 on
patient- and observer-reported clinical outcome, numerical
outcome, histological outcome and adverse effects.
Risk of bias individual/across studies
Twenty out of 37 included reports in this review used a
control group and were evaluated for risk of bias. Seven out
of 20 had a risk that was estimated low on all four sub-
divided risks. It was high on one out of four risks in six re-
ports and on two or more in seven reports. All studies have
a high risk of performance bias because microneedling
cannot be replaced by placebo treatment. The risk of bias
is summarised in Table 6.
Discussion
Microneedling has been the subject of several clinical trials
investigating its effects on atrophic acne scars, skin reju-
venation, burn scars, striae distensae, androgenetic
Table 3 Categorical measurement tools.
Scale #
Acne vulgaris Global evolution acne scale 1
Physician’s global assessment 1
Global aesthetic improvement scale 1
Androgenetic alopecia Numbered scale (0e7) 2
Atrophic acne scars Goodman and Baron 8
Echelle d’evaluation clinique des cicatrices d’acne (ECCA) 3
Quantitative Global Grading System for Postacne Scarring Instrument 3
Physicians global assessment (5-point scale) 1
Investigators global assessment 1
Numbered scale (0e5; 0e6; 0e10) 11
Global aesthetic Improvement scale 1
Scar severity score (3 grades) 2
Quartile grading scale 7
Hypertrophic scars and keloids Visual analog scale 1
Vancouver scar scale 2
Patient and observer scar assessment scale (POSAS) 2
Melasma Melasma area and severity index (MASI) 2
Skin rejuvenation Fitzpatrick wrinkle classification system 2
Numbered scale (0e5) 1
Wrinkle severity rating scale 2
Global aesthetic improvement scale 2
Quartile grading 1
Table 4 Histological measurement tools.
Haematoxylin and
Eosin
Von
Gieson
Pricorius Red Masson’s
trichrome
Silver stain IHC PCR
Aust et al. epidermal thickness
rete ridge formation
elastin
collagen
El-Domyati et al. epidermal thickness
collagen type I
collagen type II
collagen type VIII
elastin
tropoelastin
elastin new collagen
formation
El-Domyati et al. epidermal thickness
collagen type I
collagen type II
collagen type VIII
elastin
tropoelastin
elastin new collagen
formation
Khater et al. epidermal thickness
collagen fibres
fibroblasts
collagen
fibres
Lotfi et al. epidermal thickness
rete ridge formation
collagen fibres
fibroblasts
collagen
fibres
elastin fibres
Min et al. collagen fibres TGFb1
TGFb3
IL8
NFkB
collagen type I
collagen type II
GAPDH
TRFb1
TGFb3
IL8
collagen type I
Park et al. collagen fibres elastin
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Table 5 Outcomes.
Intervention Control Patient-
reported
clinical
outcome
Observer-
reported
clinical
outcome
Numerical
outcome
Histological
outcome
Adverse
effects
Acne vulgaris
CT
Kim et al. FMRF / þ þ þ (inflam >
non-inflam)
/ bleeding (5), scaling (4), cursting (6),
swelling (8), erythema (8) (all less than 1 week)
Lee et al. FMRF / þ þ þ / mild pain, oedema, bleeding (procedure);
pustular eruptions (2) <1 week
Androgenetic alopecia
RCT
Dhurat et al. MN þ minox minox þþ þþ þþ / none
CT
Dhurat et al. MN þ minox / þ þ / / none
Atrophic acne scars
RCT
Alam et al. MN negative
control
þþ þþ / / minimal pain, transient erythema and oedema
Chae et al. FMRF fractional
laser
Z Z / / FRMF: none significant
laser: pain, PIHP, acne vulgaris,
prolonged downtime
Cachafeiro et al. MN fractional
laser
Z Z / / both: crusts, pustules, erythema, pain
laser: bullae, PIH and prolonged erythema
Leheta et al. MN þ TCA fractional
laser
alternating
treatment
Z vs laser:
Z rolling
type:
þþ
boxcar type: –
icepick:
Z
vs
alternating: –
/ / both: transient pain, oedema,
erythemapeeling: desquamation
Leheta et al. MN TCA-
CROSS
Z General:
Z rolling
type:
þþ icepick
type: –
/ / Pain: – Erythema, downtime: þþ
Leheta et al. MN þ TCA TCA-CROSS Z General:
Z rolling
type: þþ
/ / Z
8
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Min et al. FMRF bipolar RF satisfaction:
þþ
pain: –
convenience: –
þþ þþ
(inflam <
non-inflam)
þþ Pain: – FMRF: transient erythema, oedema
Nofal et al. MN þ PRP TCA-
CROSS
intradermal
PRP
Z Z / / MN: erythema and oedema, pain TCA: PIH,
mild pain
PRP: pain, mild bruises (one patient)
CCT
Asif et al. MN þ PRP MN þ
distilled
water
þþ þþ / / acne, PIH, milia, persistent erythema, bruising
Chawla et al. MN þ PRP MN þ vC þþ þþ / / /
Fabroccini et al. MN þ PRP MN / þþ / / transient erythema and oedema
Sharad et al. MN þ GA peel MN / þþ / / transient erythema, PIH
Puri et al. MN TCA-
CROSS
e Z / / MN: transient erythema, pain; oedema TCA: PIH
CT
Dogra et al. MN / þ þ / / postinflammatory hyperpigmentation, tram
track, small ecchymosis
El-Domyati et al. MN / þ þ / Z (1 month)þ
(3 months)
facial oedema, slight pain, mild erythema
Fabroccini et al. MN / / þ þ / erythema, bruising over bony prominence
Fabroccini et al. MN / / þ þ / /
Imran Majid MN / þ þ / / temporary erythema, postinflammatory
hyperpigmentation (one patient), mild crusting
Lotfi et al. MN / þ þ / / transient erythema, mild to severe pain during
procedure
Kaftan et al. MN / / þ / / /
Burn scars
RCT
Busch et al. MN þ
NCASCS
MN,
neg co
Z Z þþ / /
CT
Aust et al. MN / þ þ / þ swelling and bruising
Hypertrophic scars and keloids
RCT
Fabbrocini et al. MN þ
SG
SG / þþ Z / /
Melasma
RCT
Budamakuntla et al. MN þ TA injection TA / Z / / itching, burning, erythema
CCT
(continued on next page)
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Table 5 (continued )
Intervention Control Patient-
reported
clinical
outcome
Observer-
reported
clinical
outcome
Numerical
outcome
Histological
outcome
Adverse
effects
Fabroccini et al. MN þ
depigmenting
serum
depigmenting
serum
/ þþ þþ / transient erythema and oedema
Skin rejuvenation
RCT
Lee et al. MN þ
hESC-EPC
MN Z þþ þþ / mild desquamation (one patient)
mild pain, transient erythema
CT
El-Domyati et al. MN / þ þ / þ slight pain, erythema, oedema
Fabroccini et al. MN / / þ þ / mild oedema, erythema and swelling
(48e72 h)
Fabroccini et al. MN / / þ þ /
Gold et al. FMRF / / þ / / mild-moderate erythema and oedema, pain
Kim et al. FMRF / unclear þ / / minimal pain, bruising (1 week) crusts
Striae
CCT
Khater et al. MN fractional laser þþ þþ / þþ MN: transient mild erythema
laser: PIH
CT
Park et al. MN / þ þ / þ pain, erythema, spotty bleeding, pruritus
Legend: þþ: statistically significantly different in advantage of microneedling; þ: statistically significantly better in prospective clinical trial; Z: no statistically significant difference
between the therapy regiments; -: statistically significantly worse in prospective clinical trial; –: statistical significantly different in disadvantage of microneedling; /: no data;
FMRFZ fractional microneedling radiofrequency; MNZ microneedling; TCAZ trichloroacetic acid; PRPZ platelet rich plasma; vCZ vitamin C; GAZ glycolic acid; SGZ silicone gel;
NCASCS Z non cultured stem cell suspension; h-ESC EPC Z human embryonic stem cells-endothelial precursor cells; PIH Z post-inflammatory hyperpigmentation; CSL Z casual sebum
level; SER Z sebum excretion rate.
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Microneedling: A systematic review of the literature 11alopecia, melasma and acne vulgaris. It has been compared
to other treatments such as fractional lasers, topical
products and peelings.
To strengthen the validity of the research, some trials
used control groups, randomisation and single blinding.
Measurement was made through scoring the assessors’ and
patients’ findings on scales, numeric measurement tools
and histological evaluation on skin biopsy. Microneedling
triggers regenerative mechanisms and activates non-
inflammatory wound healing in the treated skin. It acti-
vates the release of cytokines and molecules that
communicate to induce skin cell proliferation and differ-
entiation, neoangiogenesis and collagen formation.Table 6 Risk of bias.
Selection bias Detection bias
Randomisation Blinding assessor
Androgenetic alopecia
RCT
Dhurat et al. low low
Atrophic acne scars
RCT
Alam et al. low low
Chae et al. low (*) low
Cachafeiro et al. low low
Leheta et al. low low (*)
Leheta et al. low (*) low (*)
Leheta et al. low low (*)
Min et al. low (*) low
Nofal et al. low (*) low
CCT
Asif et al. high unclear
Chawla et al. high high
Fabroccini et al. high unclear
Jaishree S et al. high high
Puri et al. high high
Burn scars
RCT
Busch et al. low high
Hypertrophic scars and keloids
RCT
Fabbrocini et al. low (*) high
Melasma
RCT
Budamakuntla et al. low high
CCT
Fabroccini et al. high high
Skin rejuvenation
RCT
Lee et al. low low
Striae
CCT
Khater et al. high high
(*) no randomisation tool mentioned
(*) subjective outcoBiopsies of the treated sites showed an epidermal thick-
ening and increased collagen deposition in a normal woven
pattern.
The investigated literature lacked the methodological
unity to be included in a meta-analysis. However,
microneedling has shown to be a safe and effective
therapeutic modality for the treatment of atrophic scars,
ageing and skin disorders and proved to be useful for the
admission of topical products and radiofrequency. It
succeeded to deliver results that could complement and,
in some cases, replace the more invasive therapeutic
regimens while showing less side effects and shorter
downtime.Attrition bias Reporting bias
Exclusion, withdrawal All outcomes reported
high low (*)
low low (*)
low low
high low
low high
low low
low low
low low
low low
low low (*)
low high
low low ()
low low ()
low high
low high
low low ()
high low
low low ()
low low (*)
low low (*)
(*): statistics incomplete
(): no patient reported outcome
me data by one assessor
12 L. Ramaut et al.Summary of evidence
The use of needles for non-ablative skin treatment was first
described by Orentreich and Orentreich in 1995 as subcision
surgery, which is the release of depressed scars and wrinkles
with a needle from their attachment to the underlying skin.
This controlled trauma leads to the formation of connective
tissue to fill the created gap.41 A few years later, in 1997,
Camirand and Doucet introduced tattooing without pigment
as Needle Dermabrasion and proposed it as a technique to
improve the appearance of achromic, hypertrophic and un-
sightly scars.42 However, this device never gained wide
popularity due to the tight grouping of the needles, which
made it prone to over-treating and scarring. In 1996, skin
needling using a roller device was introduced by Fernandes
at the International Society of Aesthetic Plastic Surgery
(ISAPS) congress in Taipei.43 Fernandez designed his pilot
roller device as a drum-shaped tool with a cylinder with
3 mm needles that reach the fibroblasts deep in the reticular
layer. However, this needle length proved to be way too
painful to use in an office setting, and it caused unaccept-
able bleeding and bruising for the patient. Zeitter et al.
confirmed the observation that Fernandes made in 2008 that
1 mm needles show similar results to 3 mm needles, with the
extra advantage of less downtime, swelling and pain3,44Methodology of the included studies
The validity of the study results is determined by the
methodological setup. Thirteen of the 37 included study
setups used randomization, 10 included single-blindation
and two performed a power analysis for sample size9,45 to
improve methodological quality.
There was a noticeable difference in treatment regi-
mens. Patients were treated between 1 and 12 times with
treatment intervals varying from 1 to 8 weeks. There is no
standard treatment protocol available, but Zeitter et al.
(2014) performed a study on rats to investigate the effects
of repetitive treatments. They observed the best results
when the treatment was repeated four times with an in-
terval time of 3 weeks.44 The choice of needle length de-
pends on the pursued depth of therapeutical intervention
(e.g. thick scar tissue) and requires generalised anaesthesia
for needles longer than 2 mm.
A second striking difference was observed in the time to
follow up, which varied between 1 and 72 weeks. Studies
that performed interim follow-up evaluations observed that
the effects of microneedling changed over several months
to reach a maximum at 12e24 weeks. Fabroccini et al. even
reported the most significant results at 8e12 months post
treatment.34 This means that the 25 studies that had
follow-up times shorter than 24 weeks might have under-
estimated the effects of microneedling.
Scales were used to objectify clinical outcomes reported
by patients and observers. The heterogeneity in the used
scales made it impossible to combine different study samples
in a meta-analysis. The Goodman and Baron scale for the
evaluation of atrophic acne scars was the most universally
used evaluation scale.46 Second was the use of a numbered
scale, like the Visual Analog Scale, but unfortunately there
were differences in thenumbers given to themaximumscore.Histological measurement was based on the knowledge
gained from animal studies about the histological changes
that appear after microneedling. The increase in epidermal
thickness, increased collagen and elastin deposition and
the presence of non-inflammatory cytokines and growth
factures like TGF-b3 are measurable to demonstrate effi-
cacy.2,44,47 Researchers may be reluctant for the labour
intensity of a histological evaluation, but the importance of
histological outcome parameters is highlighted from the
scarceness of objective measurements of changes in skin
quality.
Fifty percent of the studies that used a control group did
not report a complete statistical analysis. Outcome data
from two study groups should be weighed statistically to
identify a significant difference compared to baseline and
between groups. Only three studies calculated the signifi-
cance between groups, three other studies calculated only
the comparison of each group to baseline and Puri et al.
(2015) did not perform either analysis.15 The remaining
three were incomplete because there was no statistical
analysis performed on any of their outcome parameters.
These shortcomings were accounted for in the estimation of
the reporting bias (Table 6, marked with (*)).
Outcomes of the included studies
In the current literature,microneedlingwas investigated in a
variety of settings. First, it gained evidence for its use on
atrophic acne scars. Compared to lasers and peels, micro-
needling caused comparable clinical results to these main-
stream therapies but with an explicit advantage because of
its lower risk of side effects. Hypertrophic scars are less
investigated, and a hypertrophic tendency in the patient is
often an exclusion criterion in trials that use microneedling.
The rationale behind this is that triggering skin formation
does not fit in a state of hypertrophic tendency. The few
existing trials that did include hypertrophic scars did note
the advantages of microneedling especially when combined
with topical products that aid repigmentation.
Second, microneedling enhances penetration of topical
products. It appeared to increase the effectiveness of
topically applied minoxidil on androgenetic alopecia and
depigmenting serum on melasma. Other topical products
enhanced the percutaneous collagen induction by providing
extra growth factors such as PRP for atrophic acne scars
and h-ESC-EPC for skin rejuvenation. Badran et al. (2009)
investigated the penetration of topically applied radio-
labelled mannitol into full thickness human skin grafts
spontaneously and combined with microneedling. Hydro-
phylic compounds like mannitol are expected to have a
poor penetration by passive diffusion through the stratum
corneum. The authors also noticed differences in penetra-
tion between two drug carrier fluids (invasomes or buffer
solution), which implicates that the nature of the topical
products plays a role in the effectiveness of the combina-
tion therapy.48
The delivery of radiofrequency through insulated paired
microneedles proved to improve the aesthetic appearance
of atrophic acne scars, ageing skin and acne vulgaris and
showed to be superior compared to the effects of bipolar
radiofrequency.7 It demonstrates beneficial effects on in-
flammatory lesions, which contradicts the commonly used
Microneedling: A systematic review of the literature 13exclusion criterion for microneedling, i.e. the presence of
active skin infection and inflammation. This criterion ex-
cludes patients with active acne, which is often still present
in patients with atrophic acne scars. Some studies opted for
topical or oral antibiotic prophylaxis,30,45,49 but none of the
reports included in this review mentioned bacterial in-
fections after microneedling. In-vitro studies have shown
that there is a transdermal passage of microorganisms
through the micropores after microneedling, but there is no
increased risk of infection when microneedling is performed
with standard hygienic measurements like a sterile device
and skin disinfection. It even showed less contamination
compared to intradermal needling.50
Frequently reported adverse effects are transient ery-
thema, oedema and pain. Very rare cases of post-
inflammatory hyperpigmentation,18,49 a side effect that is
commonly reported after the use of lasers and peelings, are
assumed to have appeared after not following instructions
to protect the treated skin from sunlight for a few days.
The appearance of the ‘tram track scarring’ was described
by Dogra et al., and in one case report, the authors
concluded that the scarring occurred due to high pressure
on the needling and the use of long needles over bony
prominences.51 A second case report described allergic
reaction and systemic hypersensitivity after microneedling
in three patients. These problems were caused by the use
of a topical product that was not suitable for deep admin-
istration and the use of a product that had earlier caused
hypersensitivity in the patient.52 These events illustrate
that even though microneedling is a simple and non-
invasive therapeutical option, there is a need for clear
and evidence-based guidelines to avoid these undesired
side effects or complications.
Future research
Future research should aim for a strengthening of the cur-
rent evidence by conducting more qualitative randomised
controlled clinical trials with standardised measurement
tools and lengthy follow-up times. In addition, the effects
of microneedling on hypertrophic scars and keloids have not
been examined properly and thus need further research.
This could truly establish the evidence that would pose
microneedling as a valuable evidence-based treatment
option for treating scars, wrinkles and other skin
conditions.
Strengths and limitations of this review
The strength of this review lies in the fact that it provides a
complete overview of the current use of microneedling.
The shortcomings of the current literature involving
microneedling were highlighted to serve as a guideline for
future research.
The main limitation of this study is the inability to
perform a meta-analysis due to the heterogeneity of the
included studies. The main objective of this review was to
give an overview of the current literature, which includes
the mentioning of less qualitative studies. These interfered
with the possibility to cluster the qualitative study out-
comes into a general conclusion.Conflict of interest
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